Methyl 1-Methyl-5-(4-Methylbenzoyl)-1H-Pyrrole-2-Acetate

Methyl 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetate functions as the penultimate intermediate in the commercial synthesis of Tolmetin Acid Dihydrate, an NSAID classified under ATC code M01AB11. The manufacturing process for the active moiety is governed by ICH Q7 GMP for APIs; residual solvent limits adhere to ICH Q3C Option 1 thresholds, with methanol typically controlled below 3000 ppm and toluene below 890 ppm in the final dried acid. In documented production-scale batches conducted in 5000 L glass-lined reactors, the molar ratio of ester to sodium hydroxide is maintained between 1:1.15 and 1:1.25, which corresponds to a mass fraction of approximately 18–22% w/w ester relative to the total aqueous caustic charge. Exceeding a hydroxide stoichiometry of 1:1.35 induces a 0.8–1.4% increase in the pyrrole ring-opening byproduct (EP Impurity D) that co-crystallizes during acidification and cannot be purged by a single recrystallization cycle. The downstream process requires charging pre-heated purified water at 55 °C ± 2 °C with the flaked ester introduced under subsurface nitrogen sparging to suppress oxidative discoloration; agitation is sustained at 85–95 rpm via a retreat-curve impeller for 4–6 h until in-process HPLC shows residual ester < 0.5% area. Carbon treatment (0.5% w/w activated charcoal, Darco KB-B grade) is performed at 60 °C for 30 min, followed by depth filtration through 0.45 µm polypropylene cartridges. Acidification employs 6 M hydrochloric acid added via dip tube at a controlled linear rate of 2.5 L·min⁻¹ until pH 5.0 is reached at 12 °C ± 2 °C; a deviation > 0.3 pH units towards the isoelectric point (~4.2) causes oiling-out and irreversible agglomeration. Crystallization proceeds under a programmed cooling ramp from 12 °C to 0–2 °C over 4 h, and the slurry is dewatered in a bottom-discharge centrifuge with 0.1 mm polypropylene filter cloth. The wet cake is washed with chilled purified water until conductivity < 25 µS·cm⁻¹ and dried in a double-cone vacuum dryer at 45 °C (pressure < 10 mbar) to a final moisture content ≤ 0.5%. The terminal article, Tolmetin Acid Dihydrate, is supplied as a white crystalline powder with particle size D₉₀ typically controlled to 150–250 µm for subsequent salt formation; it meets USP Tolmetin Sodium monograph precursor requirements and is packaged in 25 kg PE-laminated fibre drums under nitrogen overlay to prevent hydrolytic ester reversion during ocean freight.

Preparation of sterile-grade Tolmetin Sodium employs a direct, telescoped hydrolysis-salification sequence that eliminates isolation of the free acid intermediate, thereby reducing bioburden ingress and endotoxin accumulation. The ester is charged at a molar ratio of 1:1.02 relative to USP-grade sodium hydroxide dissolved in a solvent system composed of 95% ethanol and Water for Injection (WFI, USP) at a ratio of 70:30 v/v. The high alcohol fraction suppresses proton-transfer side reactions that generate the N-methylpyrrole decarboxylated impurity; however, a solvent composition below 65% ethanol triggers an observable exotherm and a 12–15% yield loss due to ester saponification competing with desired hydrolysis kinetics. After 3 h at reflux (78 °C ± 1 °C), the reaction is concentrated under vacuum at < 40 °C to reduce ethanol content to < 10% v/v, and the resulting aqueous sodium salt solution is passed through a series of 0.22 µm sterilizing-grade PVDF membrane filters into a Grade A isolator. Sodium salt precipitation is induced by slow addition of acetone (antisolvent ratio 1:5 v/v) under high-shear rotor-stator mixing at 3000 rpm, and the slurry is aged at −5 °C to 0 °C for 8 h to maximize dihydrate crystal form purity conforming to USP <941> XRPD reference data. Terminal drying is performed in a lyophilizer with shelf temperature ramping from −40 °C to 25 °C over 24 h under 50 µbar vacuum, yielding Tolmetin Sodium Dihydrate with endotoxin ≤ 0.15 EU·mg⁻¹, elemental impurities aligned with ICH Q3D Route 1 parenteral PDE cut-offs, and total aerobic microbial count < 10 CFU·g⁻¹. The finished dosage form includes lyophilized powder for reconstitution and ready-to-use solution in 2 mL amber ampoules at a 200 mg·mL⁻¹ concentration.

From Ester to Injectable Tolmetin Sodium: Direct Salt Precipitation Parameters

The solvent-mediated direct salt formation route significantly alters the impurity profile compared to the two-step acid isolation method. In the telescoped process, EP Impurity F (the residual ester itself) must be reduced to < 0.10% because the absence of an intermediate acid crystallization step removes the primary purge point. Manufacturers operating in FDA-inspected facilities under 21 CFR 211 typically deploy in-line FTIR monitoring of the ester carbonyl stretching band at 1735 cm⁻¹ to determine reaction completion within ± 0.3% conversion accuracy. Adjustment of ethanol-to-WFI ratio serves as a critical process parameter: a ratio above 85:15 retards hydroxide nucleophilicity and prolongs reaction time beyond 8 h, while a ratio below 65:35 increases the polarity enough to solubilize the generated sodium salt, thereby shifting the equilibrium back toward the ester and elevating the residual ester content in the precipitated API by 0.6–0.9%. Antisolvent crystallization with acetone at −5 °C has been correlated with a 0.04% carryover of mesityl oxide condensation byproducts if the acetone feedstock contains > 0.3% water; therefore, anhydrous acetone dried over molecular sieve 3A is specified. The final Tolmetin Sodium Dihydrate is analyzed per USP <791> for pH (6.5–8.5), USP <921> for water content (6.0–7.5%), and USP <621> for chromatographic purity, and is supplied in 5 kg and 25 kg LDPE bags inside HDPE containers for cold-chain distribution when intended for injectable formulation.

For veterinary anti-inflammatory preparations targeting canine osteoarthritis and equine musculoskeletal pain, the ester serves as the designated starting material in the manufacture of Tolmetin Sodium conforming to VICH GL18 residual solvent residue levels for oral administration to companion animals. Synthesis is generally conducted in dedicated non-dedicated equipment with validated cleaning procedures to prevent cross-contamination of human API lines. The validated process employs a molar ratio of ester to sodium hydroxide of 1:1.30 to compensate for caustic loss in steel reactors operated at 50–55 °C over a shortened 3.5 h hydrolysis window; the elevated stoichiometry necessitates a post-reaction pH adjustment to 5.0 ± 0.1 using 1 M acetic acid rather than HCl to minimize chloride-induced pitting corrosion in SS316L vessels. The acidified Tolmetin Acid intermediate is extracted into isopropyl acetate at 45 °C, washed with 10% w/w brine, and back-extracted into aqueous NaOH to regenerate the sodium salt, which is spray-dried at an inlet temperature of 180 °C to yield a free-flowing amorphous powder with tapped density of 0.42–0.55 g·mL⁻¹. This spray-dried material is directly compressible with microcrystalline cellulose (Avicel PH-102) and crospovidone to produce chewable tablets at strengths of 200 mg and 400 mg toluettin. The finished veterinary dosage form passes USP <2040> disintegration (≤ 15 min in simulated gastric fluid) and complies with FDA-CVM guidance for Type A medicated articles, with a target impurity ceiling of ≤ 0.5% for any single unspecified degradant.

Why does the methyl ester appear as Pharmacopoeial Impurity F and how is it produced as a reference standard?

The compound is codified in the European Pharmacopoeia (Ph. Eur. 11.3) monograph for Tolmetin Sodium as Impurity F, a late-eluting process-related substance generated from incomplete hydrolysis or transesterification events during API manufacture. Its retention time relative to the main peak (RRT approximately 1.35–1.42) and UV molar absorptivity at 320 nm make it a critical marker for system suitability testing under USP <621> and Ph. Eur. 2.2.46. Production of the impurity as a certified reference standard requires isolating the ester from mother liquors of commercial Tolmetin Acid batches or via a dedicated esterification of Tolmetin Acid using methanolic HCl under strictly anhydrous conditions. The crude isolate is purified on a preparative HPLC system equipped with a C18 column (10 µm, 250 mm × 50 mm) and a mobile phase of acetonitrile:phosphate buffer pH 3.0 (55:45 v/v) at a flow rate of 80 mL·min⁻¹; fraction pooling by UV threshold at 315 nm yields a purity > 99.5% area. Acetonitrile is stripped on a rotary evaporator at < 35 °C, and the aqueous residue is lyophilized to afford a fluffy white powder that is verified by quantitative NMR against a NIST-traceable internal standard. The material is aliquoted under argon into 10 mg and 50 mg Type I glass vials sealed with PTFE-lined crimp caps and is stored at −20 °C ± 5 °C. Each shipment is accompanied by a Certificate of Analysis conforming to ISO 17034:2016 and includes purity (HPLC-DAD), water content (Karl Fischer, < 0.2%), residual solvents (GC-HS), and identity (IR spectrum matching reference). The product serves as a quantitation reference in batch release testing of Tolmetin Sodium API for global generic manufacturers seeking ANDA approvals under USP <1225> validation guidelines.